Syndax Pharmaceuticals, Inc.
SNDX
$10.99
$0.292.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -84.85M | -94.17M | -84.13M | -68.06M | -72.40M |
| Total Depreciation and Amortization | -- | 0.00 | 2.00K | 3.00K | 3.00K |
| Total Amortization of Deferred Charges | 112.00K | 30.00K | -- | -- | -- |
| Total Other Non-Cash Items | 7.00M | 9.57M | 9.17M | 6.49M | 5.32M |
| Change in Net Operating Assets | -17.43M | 27.19M | 12.63M | -10.07M | -16.47M |
| Cash from Operations | -95.16M | -57.39M | -62.32M | -71.65M | -83.55M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 94.14M | -268.97M | 86.85M | 61.75M | -99.40M |
| Cash from Investing | 94.14M | -268.97M | 86.85M | 61.75M | -99.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 930.00K | 3.77M | 3.10M | 676.00K | 2.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 343.65M | -- | -- | -- |
| Cash from Financing | 930.00K | 347.43M | 3.10M | 676.00K | 2.17M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -90.00K | 21.06M | 27.62M | -9.22M | -180.78M |